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Visual abstract 22 
Key question: What is the randomised controlled trial evidence for different cardioplegia 23 
strategies in paediatric cardiac surgery? 24 
Key findings: 26 small, single-centre trials identified. Heterogeneity of patients, interventions 25 
& outcomes prohibited meta-analysis. 26 
Take-home message: There are no late phase clinical trials of cardioplegia in children; high-27 
quality, multi-centre trials should be conducted to improve care. 28 
 29 
Central image: PRISMA flow diagram of study selection. 30 
  31 
3 
 
Abstract 32 
Objectives: Cardioplegia is the primary method for myocardial protection during cardiac 33 
surgery. We conducted a systematic review of randomised controlled trials of cardioplegia in 34 
children to evaluate the current evidence-base. 35 
Methods: We searched MEDLINE, CENTRAL and LILACS, and manually screened retrieved 36 
references and systematic reviews to identify all randomised controlled trials comparing 37 
cardioplegia solutions or additives in children undergoing cardiac surgery published in any 38 
language; secondary publications and those reporting inseparable adult data were excluded. 39 
Two or more reviewers independently screened studies for eligibility and extracted data; the 40 
Cochrane Risk of Bias tool was used to assess for potential biases. 41 
Results: We identified 26 trials randomising 1,596 children undergoing surgery; all were 42 
single centre, phase II trials, recruiting few patients (median 48, IQR 30-99). The most 43 
frequent comparison was blood versus crystalloid in 10 (38.5%) trials and the most common 44 
endpoints were biomarkers of myocardial injury (17, 65.4%), inotrope requirements (15, 45 
57.7%) and length of stay in intensive care (11, 42.3%). However, the heterogeneity of 46 
patients, interventions and reported outcome measures prohibited meta-analysis. Overall 47 
risk of bias was high in 3 (11.5%), unclear in 23 (88.5%) and low in none. 48 
Conclusions: The current literature on cardioplegia in children contains no late phase trials. 49 
The small size, inconsistent use of endpoints and low quality of reported trials provides a 50 
limited evidence-base to inform practice. A core outcome set of clinically important, 51 
standardised, validated endpoints for assessing myocardial protection in children should be 52 
developed to facilitate the conduct of high-quality, multi-centre trials. 53 
PROSPERO registration: CRD42017080205 54 
Key words: systematic review, clinical trials, cardioplegia, myocardial protection, paediatric 55 
cardiac surgery  56 
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Introduction 57 
The use of cardioplegia has been fundamental to the intracardiac repair of congenital heart 58 
lesions for over 40 years. In conjunction with hypothermia, it remains the primary method for 59 
myocardial protection against ischemia-reperfusion injury during cardiac surgery, inducing 60 
electromechanical arrest to allow access to a still and bloodless field. Cardioplegic arrest 61 
reduces myocardial oxygen uptake to only 10% of the perfused beating heart, and 62 
progressive hypothermia leads to a further stepwise reduction [1]. However, myocardial 63 
damage still occurs routinely following ischemia-reperfusion, as demonstrated by the 64 
universal release of troponin [2]. Ventricular dysfunction may follow repair of even the 65 
simplest lesions [3], manifesting as low cardiac output and requiring inotropic support in the 66 
early postoperative period. The immature myocardium exhibits marked differences from the 67 
adult heart, including substrate metabolism, calcium handling, insulin sensitivity and 68 
antioxidant defence against free radicals [4]. Current cardioplegia techniques are primarily 69 
derived from adult or laboratory models and may not be optimal for young children, 70 
especially neonates and those with preoperative cyanosis [5-7]. 71 
Recent surveys of practice have shown marked variations in the use of commercially-72 
available and customised cardioplegia solutions in children in North America [8] and 73 
worldwide [9]. The composition, dilution, dose, temperature, route of administration and time 74 
interval between doses varied between surgeons and continents, but few surgeons adjusted 75 
their technique according to the age of the patient [8]. These findings suggest that the choice 76 
of solution is determined primarily by the individual surgeon, institution or country rather than 77 
the physiology of the patient, and that this may be due to a lack of evidence to support one 78 
technique over another. We therefore conducted a systematic review of all randomised 79 
controlled trials (RCTs) of cardioplegia in paediatric cardiac surgery to evaluate the value 80 
and quality of the current evidence-base.  81 
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Methods 82 
This review was conducted with reference to the Cochrane handbook for systematic reviews 83 
of interventions [10,11] and reported in accordance with the PRISMA statement [12]. All 84 
eligibility criteria, search terms and data items were prespecified and the review was 85 
prospectively registered on PROSPERO (CRD42017080205) 86 
(https://www.crd.york.ac.uk/PROSPERO). 87 
 88 
Trial eligibility 89 
All randomised and quasi-randomised clinical trials comparing cardioplegia solutions or 90 
additives in children undergoing cardiac surgery published in any language were included. 91 
The definition of a child was based upon the authors’ characterization and cardioplegia was 92 
defined as a solution injected into the cardiac vasculature during surgery with the aim of 93 
causing electromechanical arrest. 94 
Trials were excluded if the outcome measures were not related to the use of cardioplegia for 95 
myocardial protection. Those including both adults and children were only included if the 96 
publication presented the paediatric data separately. Secondary publications, sub-studies or 97 
long-term outcomes of previously reported trials were excluded unless the results were 98 
specifically related to cardioplegia when the original report was not. Trials published only as 99 
a conference abstract or for which all options to obtain the full text publication were 100 
exhausted, were excluded due to insufficient data for analysis. 101 
 102 
Search strategy 103 
We searched international primary research databases (MEDLINE, CENTRAL, LILACS) 104 
from inception to October 31, 2017 and reference lists of relevant articles, systematic 105 
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reviews and meta-analyses to identify all eligible studies. We combined previously validated 106 
search strategies to identify randomised controlled trials, studies including children and 107 
those using cardioplegia as an investigational medicinal product (see supplemental material 108 
for detailed search terms). For example, to identify RCTs in MEDLINE, we used the 109 
Cochrane Highly Sensitive Search Strategy for identifying randomised trials: sensitivity- and 110 
precision-maximizing version [10] and to identify studies including children, we adapted the 111 
improved Cochrane Childhood Cancer Group filter for PubMed developed by Leclercq and 112 
colleagues [13]. 113 
 114 
Study selection and data extraction 115 
Abstracts and then full text publications of all identified articles were screened independently 116 
by two reviewers (IY and NED) to generate a database of included studies. Data were 117 
extracted independently by two reviewers (two of IY, AJP, NKO, C-RC and NED) from the 118 
full trial publication and any published protocols or supplemental material; any assessments 119 
of trials in previous systematic reviews were corroborated. A full list of data items, 120 
descriptors is available in the supplemental material. Any disagreements on study selection 121 
or data extraction were resolved by consensus. Non-English language articles were 122 
evaluated in conjunction with individuals with a clinical or research methodology background 123 
and fluent in that language (C-RC for Chinese, see acknowledgements). 124 
 125 
Risk of bias assessment 126 
The Cochrane Risk of Bias Tool was used to define the risk of bias for each of the included 127 
trials according to the following domains: sequence generation, allocation concealment, 128 
blinding of participants, personnel and outcome assessors, incomplete outcome data, 129 
selective outcome reporting and other potential threats to validity [11]. Trials were rated as 130 
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low risk, unclear or high risk of bias for each factor; overall risk of bias was determined for 131 
each trial as low (low risk in all domains), high (high risk of bias in one or more domains) or 132 
unclear (neither of the above). 133 
 134 
Statistical analysis 135 
Statistical analysis was performed using R (https://www.r-project.org/). All continuous data 136 
were expressed as medians with interquartile ranges (IQR) and categorical data as counts 137 
and percentages where relevant. Pearson correlation was used to assess the relationship 138 
between the number of children randomised per trial and the year of publication. 139 
The corresponding author had full access to all the data in the study and had final 140 
responsibility for the decision to submit for publication. 141 
  142 
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Results 143 
From 132 unique records, we identified 26 RCTs published to October 31, 2017, 144 
randomising 1,596 children undergoing surgery with cardioplegic arrest, of whom 1549 145 
(97.1%) were included in analysis of the primary endpoint. The flow of studies through the 146 
systematic review process is documented in figure 1. All full text articles were sourced 147 
online, via national libraries or directly from the authors; references of included trials are 148 
listed in the supplementary material. 149 
Characteristics of the included trials are shown in table 1. All studies were single centre, 150 
phase II trials, originating from 11 countries, with China (9, 34.6%), Japan (4, 15.4%) and 151 
Turkey (3, 11.5%) being the most frequent and only one (3.8%) from the United States. Eight 152 
(30.7%) trials were published in a language other than English: 7 (26.9%) in Chinese and 153 
one (3.8%) in Turkish. Trials were most commonly published in specialist cardiothoracic 154 
surgery journals (14, 53.8%) with none reaching high-impact cardiovascular or general 155 
medical journals. 156 
The number of children randomised ranged between 20 and 138 with a median of 48 (IQR 157 
30-99). Only 4 (15.4%) trials analysed fifty or more patients per arm and the median duration 158 
of recruitment was 12 months (IQR 6-16.5). The median age of patients was 29.5 months 159 
(IQR 18.2-54.0) and just 21 (1.4%) neonates (confirmed or probable) were included; no trial 160 
specifically assessed the use of cardioplegia in neonates. There was no significant 161 
correlation between the number of patients recruited per trial and the year of publication (R -162 
0.19). Most surgical procedures were low risk with 255 (16.4%) children undergoing 163 
operations with a Risk Adjusted classification for Congenital Heart Surgery (RACHS-1) score 164 
of 3 or above [14] and the mean aortic cross-clamp time across studies was 60 minutes. The 165 
most frequent comparison was blood versus crystalloid cardioplegia in 10 (38.5%) trials 166 
followed by various additives in 6 (23.1%) trials (table 1). 167 
 168 
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Outcome measures 169 
Thirteen trials (50.0%) had a defined primary endpoint, one of which (cardiac index) was a 170 
clinical outcome; none reported mortality as the primary endpoint. The most common 171 
outcome measures were biomarkers of myocardial injury (17, 65.4%), inotrope requirements 172 
(15, 57.7%) and length of stay in intensive care (11, 42.3%) (table 2). However, there was 173 
marked heterogeneity within endpoints relating to the metrics of assessment used (table 3). 174 
Serum biomarker assays of myocardial injury were: cardiac troponin (cTn) in 13 (50.0%), 175 
specifically the cTn-I subunit in 11 (42.3%) and cTn-T subunit in 3 (11.5%); serum creatine 176 
kinase MB isoenzyme (CK-MB) in 8 (30.8%); and heart-type fatty acid binding protein (h-177 
FABP) in 2 (7.7%). These measures were inconsistently reported as concentrations at 178 
timepoints from reperfusion to 48 hours, peak value, total release/activity, and area under 179 
the time-concentration curve (AUC); scheduling of sample collection was variable and timed 180 
from reperfusion, end of CPB, end of surgery or arrival on ICU. Similarly, inotrope use was 181 
reported as binary need for support, dose at the end of surgery or postoperative intervals, 182 
maximal dose, total dose in the first 24 hours, duration of use and various inotrope scores 183 
over differing time periods. The heterogeneity of patients, interventions and reported 184 
outcome measures thereby prohibited meta-analysis. Only short-term outcomes up to 185 
discharge or 30 days were reported. 186 
 187 
Quality of trials 188 
Regarding standards for the conduct and reporting of clinical trials, [15] 4 (15.4%) performed 189 
a sample size calculation, 2 (7.7%) were prospectively registered on a publicly-accessible 190 
trial database, and 2 (7.7%) published a CONSORT flow diagram. None of the 26 trials were 191 
overseen by an independent Data Monitoring Committee and none were stopped early or 192 
extended. 193 
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Risk of bias assessment for each of the eight domains and overall is shown in figure 2. 194 
Overall risk of bias was high in 3 (11.5%) trials, unclear in 23 (88.5%) and low in none; the 195 
high proportion of unclear resulted from poor reporting of randomisation and masking 196 
procedures, and an inability to exclude selective reporting due to a lack of trial registration or 197 
published protocol. 198 
  199 
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Discussion 200 
RCTs represent the gold standard in evaluating healthcare interventions through rigorous 201 
testing of a predefined protocol and minimization of bias [15]. Yet in this systematic review of 202 
the published literature, we identified only 26 RCTs of cardioplegia in paediatric cardiac 203 
surgery; these were exclusively single centre, phase II trials that were rarely prospectively 204 
registered, recruited small numbers of patients, lacked independent oversight and were not 205 
reported to international standards [15-16]. Furthermore, the heterogeneity of patients, 206 
interventions and reported outcome measures across trials precluded the pooling of results 207 
for meta-analysis. Of concern is the finding that studies included few neonates, in whom 208 
myocardial metabolism and cellular homeostasis differ from the more mature heart and the 209 
effects of cardioplegia are less well understood [4]. As a result, these trials provide a limited 210 
evidence-base to support clinical decision-making on cardioplegia, a technique which is so 211 
fundamental to the surgical management of children with congenital heart disease. Whilst all 212 
cardioplegia solutions are efficacious in arresting the heart, differences in their effectiveness 213 
to reduce ischaemia-reperfusion injury and therefore improve outcomes, are unknown. 214 
 215 
Our findings reflect those of a previous, more limited meta-analysis of cardioplegia trials in 216 
children. Fang et al compared the efficacy of blood versus crystalloid cardioplegia and 217 
identified 5 RCTs published in English prior to mid-2013, recruiting 358 children in total [17]. 218 
They found no difference in cTn-I release at 4-6, 12 or 24 hours (3 trials), duration of 219 
ventilation (3 trials) or length of ICU stay (4 trials). Only blood lactate following CPB (4 trials) 220 
was significantly lower in the blood cardioplegia group but this difference was prejudiced by 221 
one study, without which there was no effect. Inotrope use was reported in all 5 trials, but the 222 
reviewers were unable to pool data due to the diverse metrics used. Risk of bias was 223 
assessed using the modified Jadad scale, a flawed method of quality assessment, with all 224 
trials classified as ‘high quality’ despite only one scoring >5 on the 8-point scale. They 225 
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concluded that there was no evidence of improvement in myocardial injury or clinical 226 
outcomes but were limited by the small number of patients and variability in age, 227 
preoperative cyanosis and techniques used. Similarly, Mylonas et al recently identified many 228 
non-randomised or retrospective studies on paediatric cardioplegia but few RCTs [18], a 229 
finding that is commonplace throughout the global paediatric cardiac surgery literature. In a 230 
recent systematic review of RCTs published since 2000, we identified few late-phase clinical 231 
trials; most were small, single-centre studies of low value, uncertain quality and at risk of 232 
systematic bias [19]. This lack of evidence to guide clinical practice fosters uncertainty and 233 
predisposes to variability in patient care. 234 
 235 
Low cardiac output syndrome following surgery is the commonest premorbid complication in 236 
children and the most frequent seminal event leading to death [20]. The ubiquitous release 237 
of troponin following aortic cross-clamping in children demonstrates that myocardial injury 238 
occurs routinely and is therefore not a problem solved [2,4]. Myocardial protection remains 239 
an area of active research; 18% of recent clinical trials in paediatric cardiac surgery 240 
evaluated cardioplegia, ischemic conditioning or other drugs to reduce myocardial injury [19]. 241 
However, the wide range of variables in cardioplegia technique has led to a potpourri of 242 
studies evaluating different aspects of practice. Of the papers identified in this review, blood 243 
versus crystalloid cardioplegia was the most common comparison (10, 38.5%) but was often 244 
combined with other differences between groups, such as warm versus cold or autologous 245 
versus allogenic blood, making direct comparison between studies more difficult and limiting 246 
meta-analysis. This variability in the techniques evaluated by clinical trials reflects the 247 
current state of clinical practice; the second most commonly used formulations of 248 
cardioplegia for children in North America are customised solutions (34%) unique to each 249 
centre [8], essentially a ‘none of the above’ homebrew, emphasizing the lack of evidence for 250 
an optimal cardioplegia solution. As such the widespread adherence to local solutions may 251 
also provide a barrier to conducting multi-centre clinical trials. 252 
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 253 
To facilitate the synthesis of findings from multiple studies, clinical trials must report valid 254 
and comparable outcome measures. We found marked variation in the reporting of 255 
endpoints between trials with inconsistent use of metrics to evaluate the same outcome 256 
(table 3). Biomarkers of myocardial injury were the most commonly used outcome measure 257 
but included one or more of serum troponin-I, troponin-T, CK-MB and h-FABP, measured at 258 
varying timepoints up to 48 hours, and variably reported as measured concentrations, peak 259 
or AUC. This disparity reflects the absence of a standardized method for reporting biomarker 260 
release after ischemia-reperfusion in children as it is unknown which metric has greatest 261 
discriminatory power. Following coronary surgery in adults, cumulative AUC troponin at 72 262 
hours has been shown to best predict mid-term mortality [21]. However, obtaining blood 263 
samples even up to 48 hours is more problematic in children, especially with expedited 264 
removal of venous lines during an uneventful recovery [22]. Newer measures of myocardial 265 
injury, such as h-FABP and high-sensitivity troponin, may have an earlier peak and greater 266 
positive predictive value [23-25] but currently lack validation in this cohort [26]. Other 267 
outcome measures also differed in their definition, timing and measurement. Inotropic 268 
support in the early postoperative period was reported using various metrics of dose, 269 
duration or a combination through an inotrope score; recently, maximum vasoactive-inotropic 270 
score has been identified as the optimal measure of pharmacologic cardiovascular support 271 
after cardiac surgery in infants and is strongly associated with morbidity and mortality [27]. 272 
Length of stay on ICU was usually recorded as actual time elapsed rather than assessed 273 
against objective criteria such as fitness for discharge. Furthermore, all trials reported only 274 
short-term endpoints with no functional or long-term outcomes. 275 
 276 
Heterogeneity of outcome measures is a common problem in systematic reviews and limits 277 
the ability to conduct meta-analyses of pooled data. The Core Outcome Measures in 278 
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Effectiveness Trials (COMET) initiative is an international effort to develop core outcome 279 
sets for clinical trials, defined as ‘the minimum that should be measured and reported in all 280 
clinical trials of a specific condition’ [28]. Yet there are currently no core outcome sets 281 
relevant to any aspect of children’s heart surgery registered on the COMET database. 282 
Endpoints such as vasoactive inotrope score [27] and duration of postoperative mechanical 283 
ventilation [29] have been validated in large datasets and should form the basis of such an 284 
endeavour. A set of standardized, evidence-based endpoints would have enabled selection 285 
of the same metrics across trials, reduced the risk of outcome reporting bias, and increased 286 
the value of individual studies by facilitating evidence synthesis. To approve new drugs, the 287 
FDA looks for endpoints that are clinically meaningful and ideally measure directly how a 288 
patient ‘feels, functions or survives’ [30]; however, none of the trials reported outcomes 289 
beyond discharge or 30 days and there is little evidence to correlate perioperative variables 290 
to the long-term functional outcomes that are most important to patients, such as exercise 291 
tolerance and quality of life. 292 
 293 
The strengths of this systematic review include the comprehensive search strategy, 294 
independent review procedures and obtainment of the full text of all potential articles in all 295 
languages. The limitations include: a risk of reporting bias, although unpublished studies 296 
would be expected to be of lower value; an inability to perform any meta-analyses to inform 297 
clinical practice due to the paucity of comparable studies; and limiting the scope to RCTs, 298 
which are not the only source of valuable evidence to inform clinical practice. 299 
 300 
Conclusions 301 
This comprehensive systematic review demonstrates that the current literature on 302 
cardioplegia in children contains no late phase trials. The small size, inconsistent use of 303 
endpoints and low quality of reported trials provides a limited evidence-base to inform clinical 304 
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practice; neonates were particularly poorly represented. This lack of evidence combined with 305 
marked variations in care [8,9] demonstrates clinical equipoise and the need for high-quality, 306 
late phase, multi-centre clinical trials to determine which of the current cardioplegic solutions 307 
provide the best myocardial protection for defined patient groups. An agreed core outcome 308 
set of clinically important, standardized, validated endpoints for assessing myocardial 309 
protection in children should be developed to facilitate the conduct of such trials and the 310 
meta-analysis of pooled data. Improving our understanding of how these perioperative 311 
endpoints relate to long-term functional outcomes will be key to improving myocardial 312 
protection, especially in those who have cumulative exposure to ischemia-reperfusion 313 
through multiple operations. 314 
  315 
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Figures 326 
 327 
 328 
Figure 1. PRISMA flow diagram of study selection. 329 
RCT, randomised controlled trial. * includes multiple counting. 330 
 331 
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 332 
Figure 2. Cochrane Risk of bias scores for included trials. 333 
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Table 1. Characteristics of included trials. 335 
 336 
Characteristic n (%)  Characteristic n (%) 
Phase II, single-centre 26 (100%)  Design  
Country of origin    Parallel groups 25 (96.2%) 
 China 9 (34.6%)   Factorial 1 (3.8%) 
 Japan 4 (15.4%)  Randomisation  
 Turkey 3 (11.5%)   Simple unrestricted 11 (42.3%) 
 Iran 2 (7.7%)   Block/stratified 1 (3.8%) 
 United Kingdom 2 (7.7%)   Unclear 14 (53.8%) 
 Belgium 1 (3.8%)  Intervention comparisons  
 India 1 (3.8%)   Blood v crystalloid * 10 (38.5%) 
 Italy 1 (3.8%)   Additives  6 (23.1%) 
 Serbia 1 (3.8%)    Herbal additive 3 (11.5%) 
 Sweden 1 (3.8%)    Non-herbal additive 3 (11.5%) 
 United States 1 (3.8%)   Warm terminal dose (hot shot) 
* 
3 (11.5%) 
Language of publication    Autologous v allogenic blood * 2 (7.7%) 
 English 18 (69.2%)   Custodiol HTK v St. Thomas’ 2 (7.7%) 
 Chinese 7 (26.9%)   del Nido v St. Thomas’ 2 (7.7%) 
 Turkish 1 (3.8%)   Warm v cold * 2 (7.7%) 
Number of arms    Celsior v St. Thomas’ 1 (3.8%) 
 Two 20 (76.9%)   Leukocyte depletion 1 (3.8%) 
 Three 6 (23.1%)   Potassium concentration 1 (3.8%) 
 337 
* includes multiple counting. HTK: Histidine-Tryptophan-Ketoglutarate. 338 
  339 
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Table 2. Defined outcome measures most frequently reported in included trials. 340 
 341 
Outcome measure n (%) 
Clinical  
 Inotrope requirements 15 (57.7%) 
 Length of stay in ICU 11 (42.3%) 
 Duration of mechanical ventilation 10 (38.5%) 
 Length of stay in hospital 7 (26.9%) 
 Cardiac output/index 4 (15.9%) 
 LV function on echocardiography 4 (15.9%) 
Non-clinical  
 Biomarkers of myocardial injury 17 (65.4%) 
 Arterial lactate 8 (30.8%) 
 Myocardial biopsy histology 5 (19.2%) 
 Myocardial biopsy ATP 4 (15.9%) 
 Biomarkers of systemic inflammation 4 (15.9%) 
 Coronary sinus lactate 3 (11.5%) 
 342 
ATP: adenosine triphosphate; ICU: intensive care unit; LV: left ventricle. 343 
  344 
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Table 3. Outcome metrics for serum biomarkers and inotropes reported in included trials. 345 
 346 
Authors Year Biomarkers of myocardial injury Inotropes 
Matsuda H et al 1989 CK-MB: peak * - 
Mori F et al 1990 CK-MB: 1, 3, 6, 12, 24, 48 h, total 
release/activity * 
Use 
Young JN et al 1997 - Inotrope score, total dose 
8 h 
Hayashi Y et al 2000 CK-MB: peak (6, 12, 18, 24 h) 
h-FABP: 50 min 
Peak dose 
Caputo M et al 2002 cTnI: AUC 48 h (4, 12, 24, 48 h) Use, duration 
Toyoda Y et al 2003 cTnT: reperfusion, 1, 3, 6, 18 h 
h-FABP: reperfusion, 1, 2, 3 h 
- 
Han HG et al 2004 - - 
Modi P et al 2004 cTnI: AUC 48 h (1, 4, 12, 24, 48 h) Duration, total dose 
Amark K et al 2006 - Total dose 24 h 
Cuccurullo L et al 2006 - - 
Deng YK et al 2006 CK-MB: end op, 6, 12, 24, 48 h 
cTnI: end op, 6, 12, 24, 48 h 
cTnT: end op, 6, 12, 24, 48 h 
- 
Deng YK et al 2007 - - 
Jin ZX et al 2008 cTnI: 1, 3, 6, 12, 24 h Duration, inotrope score: 
1, 3, 6, 12, 24, 48 h 
Deng YK et al 2009 - - 
Duvan I et al 2009 CK-MB: reperfusion, 4, 12, 24, 48 h 
cTnT: reperfusion, 4, 12, 24, 48 h 
Use, duration 
Zhang Q et al 2009 - Use 
Poncelet AJ et al 2011 cTnI: reperfusion, 6, 12, 24 h Use 
Liu Y et al 2012 cTnI: 1, 3, 6, 12, 24 h * Inotrope score: 1, 3, 6, 12, 
24, 48 h 
Cheng GC et al 2013 CK: 30 min, 24 h - 
Korun O et al 2013 - - 
22 
 
Ma C et al 2013 CK-MB: end CPB 
cTnI: end CPB 
Use 
Nezafati MH et al 2013 - - 
Kuşlu S et al 2015 CK-MB: end op, 4, 16, 24, 48 h 
cTnI: end op, 4, 16, 24, 48 h * 
Peak dose, dose: end op, 
4, 8, 12, 16, 20, 24, 48 h 
Mimic B et al 2016 cTnI: reperfusion, 1, 4, 12, 24 h * Level 24 h, duration 
Gorjipour F et al 2017 cTnI: reperfusion, 24 h - 
Talwar S et al 2017 cTnI: end CPB, 24 h VIS: 1, 2, 3, 4 d 
 347 
* indicates defined primary outcome. AUC: area under the curve; CK: creatine kinase; CK-348 
MB: creatine kinase MB isoenzyme; CPB: cardiopulmonary bypass; cTnI: cardiac troponin I 349 
subunit; cTnT: cardiac troponin T subunit; h-FABP: heart-type fatty acid binding protein; VIS: 350 
vasoactive inotrope score. 351 
 352 
  353 
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